TB R&D Weekly Update: T-Cell Surface Markers as Potential Biomarkers for TB Treatment

Henao-Tamayo M, Irwin SM, Shang S, Ordway D, Orme IM. T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis. Tuberculosis (Edinb). 2011 Apr 27. [Epub ahead of print]

In this week’s article, potential cellular biomarkers are explored in the mouse model with three potential markers: PD-1 (program death-1) and TIM-3 (T cell immunoglobulin mucin-3) on CD8 T cells and KIRG-1 (killer cell lectin-like receptor G1) on both CD4 and CD8 T cells. The search for validated biomarkers that can predict treatment success has been a difficult one. The focus of much of the research on biomarkers has been on serum markers, because of practical reasons and considerations of use in resource-limited settings. Henao-Tamayo, et al., took a different focus looking at markers on the surface of lung T cells. Key points from the article include:

  • Flow cytometry analysis was used to look at t-cell populations in the lungs of C57BL/6 mice infected with H37RV and untreated, infected with H37RV and treated with rifampicin and isoniazid, and uninfected.
  • In one set of experiments, the markers CD27, PD-1, and Tim-3 on CD8 cells were highly expressed in infected/untreated mice which was in contrast to the decrease in levels of expression with decrease in bacterial load in infected/treated mice. By the end of treatment, the infected/treated mice had expression levels of these markers similar to uninfected mice.
  • The authors looked at T cell activation marker KLRG-1 which is found on the surface of T cells. This marker was decreased in expression on both CD4 and CD8 T cells after treatment.
  • The results may not be reflected in T cells obtained from the blood but it is worth investigating in the authors’ opinion.

Additional TB R&D News:

Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux

Metabolite-enabled eradication of bacterial persisters by aminoglycosides

New Findings Reported from Georgia Institute of Technology Describe Advances in Microbial Drug Resistance

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...